KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Temporal Profile of Treatment-Emergent Adverse Events in Adult Asian Patients with Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: Post Hoc Analysis of a Phase 3, Randomized Trial.

Naotaka Usui, Dong Zhou, Bing Qin, Somsak Tiamkao, Leonor Cabral-Lim, Kheng Seang Lim, Shih-Hui Lim, Jing-Jane Tsai, Jun Watanabe, Weiwei Sun, Najla Dickson, Brian Moseley, Dimitrios Bourikas, Yushi Inoue

Adv Ther 42(11) 5639-5652

PMID40944847
PMCIDPMC12579673
DOI10.1007/s12325-025-03357-7
发表日期2025-09-13
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。
摘要

摘要

INTRODUCTION: We assessed the time course of treatment-emergent adverse events (TEAEs) in adult Asian patients (in Thailand, Japan, China, Philippines, Malaysia, Singapore, and Taiwan) with focal-onset seizures (FOS) during adjunctive brivaracetam (BRV) treatment. METHODS: Post hoc analysis of EP0083/NCT03083665, a Phase 3, randomized, double-blind, placebo (PBO)-controlled trial that evaluated BRV 50 and 200 mg/day in adult Asian patients (≥ 16-80 years) with FOS. Following an 8-week prospective baseline, patients were randomized 1:1:1 to PBO, BRV 50 mg, or BRV 200 mg and entered a 12-week treatment period. RESULTS: Overall, 448 patients (mean age 34.5 years; 53.8% female) received ≥ 1 dose of trial medication (PBO/BRV 50 mg/BRV 200 mg: n = 149/151/148 [Safety Set]). The overall incidence of TEAEs was similar across treatment arms (53.6-58.1%), and most TEAEs were mild in intensity (45.0-48.3%). Patients discontinuing BRV because of TEAEs (1.3% BRV 50 mg; 2.7% BRV 200 mg) discontinued during the first 5 weeks of treatment (for PBO, discontinuations due to TEAEs [3.4%] took place between weeks 1-8). The incidence of drug-related TEAEs was 18.1% in patients receiving PBO, 24.5% in those on BRV 50 mg/day, and 39.2% for BRV 200 mg/day; however, most were of mild intensity and did not lead to BRV discontinuation. The incidence of TEAEs and drug-related TEAEs was highest during the first week of adjunctive BRV treatment and decreased thereafter. The onset of drug-related somnolence and dizziness occurred mainly during the first week of treatment. CONCLUSION: In Asian adults with FOS, most drug-related TEAEs were mild in intensity, indicating that adjunctive BRV had a favorable tolerability profile when initiated at a potentially therapeutic dose without titration. The incidence of drug-related TEAEs including somnolence and dizziness was highest during the first week of adjunctive BRV treatment, abating thereafter. These tolerability data could help inform patient monitoring and treatment decisions when prescribing BRV. TRIAL REGISTRATION: ClinicalTrials.gov NCT03083665.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Overall incidence of ( a ) TEAEs, ( b ) drug-related TEAEs, ( c ) drug-related somnolence, and ( d ) drug-related dizziness by intensity during the 12-week treatment period (Safety Set). BRV brivaracetam, PBO placebo, TEAE treatment-emergent adverse event. Panels a and b reproduced with modifications from Fig. 1 of Usui et al. [14], licensed under CC BY
非 KM Figure
Fig. 2Fig. 2 ( a ) Incidence a and ( b ) prevalence b of TEAEs by week of treatment (Safety Set). The denominators are patients with exposure during the specified week. TEAEs commencing no earlier than week 13 are excluded. BRV brivaracetam, PBO placebo, TEAE treatment-emergent adverse event. a Proportion of patients with TEAEs with onset during the specified week of treatment. b Proportion of patients with TEAEs with onset or that were ongoing during the specified week of treatment
非 KM Figure
Fig. 3Fig. 3 ( a ) Incidence a and ( b ) prevalence b of drug-related TEAEs by week of treatment (Safety Set). The denominators are patients with exposure during the specified week. TEAEs commencing no earlier than week 13 are excluded. BRV brivaracetam, PBO placebo, TEAE treatment-emergent adverse event. a Proportion of patients with drug-related TEAEs with onset during the specified week of treatment. b Proportion of patients with drug-related TEAEs with onset or that were ongoing during the specified week of treatment
非 KM Figure
Fig. 4Fig. 4 ( a ) Incidence a and ( b ) prevalence b of drug-related somnolence by week of treatment (Safety Set). The denominators are patients with exposure during the specified week. TEAEs commencing no earlier than week 13 are excluded. BRV brivaracetam, PBO placebo, TEAE treatment-emergent adverse event. a Proportion of patients with TEAEs with the preferred term somnolence with onset during the specified week of treatment. b Proportion of patients with TEAEs with the preferred term somnolence with onset or that were ongoing during the specified week of treatment. Panel ( a ) reproduced with modifications from Fig. 2 of Usui et al. [14], licensed under CC BY
非 KM Figure
Fig. 5Fig. 5 ( a ) Incidence a and ( b ) prevalence b of drug-related dizziness by week of treatment (Safety Set). The denominators are patients with exposure during the specified week. TEAEs commencing no earlier than week 13 are excluded. BRV brivaracetam, PBO placebo, TEAE treatment-emergent adverse event. a Proportion of patients with TEAEs with the preferred term dizziness with onset during the specified week of treatment. b Proportion of patients with TEAEs with the preferred term dizziness with onset during the specified week of treatment. Panel a reproduced with modifications from Fig. 2 of Usui et al. [14], licensed under CC BY
非 KM Figure